Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather CagriSema More Biotechnology Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide